Source comparison
MK-677 Safe Long Term Use: [Type] Comparison
MK-677 (Ibutamoren) Ghrelin receptor agonist → pulsatile GH release High (60–70% develop impaired glucose tolerance by 18 months) Moderate-High (15–20% severe cases) Yes. IGF-1-driven proliferation risk 12–24 months CJC-1295/Ipamorelin GHRH analogue + selectiv
This comparison does not assign a generated winner or score.
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist → pulsatile GH release
- High (60–70% develop impaired glucose tolerance by 18 months)
- Moderate-High (15–20% severe cases)
- Yes. IGF-1-driven proliferation risk
- 12–24 months
- CJC-1295/Ipamorelin
- GHRH analogue + selective ghrelin agonist
- Moderate (30–40% glucose elevation, less severe than MK-677)
- Low-Moderate (5–10% clinically significant)
- Yes. Same IGF-1 concern
- 6–18 months typical
- Exogenous GH (Somatropin)
- Direct GH replacement
- High (dose-dependent, reversible with cessation)
- High (25–30% develop edema)
- Yes. FDA black box warning for malignancy acceleration
- Medically supervised only
- Sermorelin (GHRH)
- Growth hormone releasing hormone analogue
- Low (minimal effect on fasting glucose in trials <12 months)
- Low (<5%)
- No formal requirement in short-term use
- 6–12 months research contexts
- Bottom Line Assessment
- MK-677 produces the most sustained IGF-1 elevation of any oral GH secretagogue, which correlates with both its anabolic efficacy and its metabolic liability. It works. But the cost-benefit calculation shifts unfavorably beyond 12 months for most populations.